[{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Shares Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Announces Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Micro\u2122 Glucagon","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Megapharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xeris Pharmaceuticals Announces Distribution Agreement With Megapharm Ltd. to Commercialize Gvoke\u00ae in Israel and the Palestinian Authority","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Tetris Pharma","pharmaFlowCategory":"D","amount":"$71.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xeris Pharmaceuticals Ink License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo\u00ae in Europe","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo\u2122 for Severe Hypoglycaemia Treatment","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Receives EC Approval of Ogluo\u2122 for Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo\u00ae (Glucagon) Injection for the Treatment of Severe Hypoglycaemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Tetris Pharma","sponsor":"Arecor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xeris\u2019 Commercialization Partner for Ogluo, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"AmideBio","sponsor":"NIDDK","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"AmideBio Awarded SBIR Phase IIB Grant to Support Pre-Clinical Development of its Long-Acting Stable Glucagon Analog for the Treatment of Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Tetris Pharma","sponsor":"Arecor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetris Pharma Signs Service Agreement With Syneos Health","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,075.0 million","upfrontCash":"$625.0 million","newsHeadline":"Lilly to Divest BAQSIMI to Amphastar","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,075.0 million","upfrontCash":"$625.0 million","newsHeadline":"Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Glucagon
Amphastar intends to use the proceeds for the payment of milestone payments in connection with the acquisition of Baqsimi (glucagon) nasal powder, used to treat very low blood sugar (severe hypoglycemia) in people with diabetes ages 4 years and above.
Through the divestment, Amphastar will continue Lilly's mission to help more people benefit from Baqsimi (glucagon), the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.
Through the divestment, Amphastar will continue Lilly's mission to help more people benefit from Baqsimi (glucagon), the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.
Gvoke (glucagon) increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver.
Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycaemia.
This two-year grant will allow AmideBio to select a long-acting soluble stable glucagon candidate and do the necessary work to support the filing of an Investigational New Drug (IND) application with the FDA at the end of the grant period.
Under the terms of the proposed acquisition, Arecor Therapeutics has agreed to acquire Tetris Pharma and will continue to commercialize Ogluo in the UK and EEA. Gvoke® (US) /Ogluo® (EU), the first prescription, ready-to-use, pre-mixed, pre-measured glucagon injection.
Under the terms of the applicable agreements, Xeris will be responsible for Gvoke® PFS and Gvoke HypoPen® (glucagon injection) supply and Tetris will be responsible for the commercialization of Ogluo in the Territory.
The United Kingdom’s Medicines and Healthcare Regulatory Agency (MHRA) has approved Ogluo® (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.